LWCFA
HAE icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Haemonetics HAE Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-461
Closed -$53K – 674
2019
Q4 		$53K Hold
461
– – ﹤0.01% 410
2019
Q3 		$58K Buy
+461
New +$58.5K ﹤0.01% 394

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's HAE Position: Q1 2020 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Haemonetics (HAE) in Q1 2020, closing a stake of 461 shares — an estimated $53K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in HAE in Q3 2019 and held it in 2 quarters. The position peaked at $58K in Q3 2019. 269 funds tracked by Wall St. Rank hold HAE as of Q1 2020.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Haemonetics position as of Q1 2020 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 461 Haemonetics shares in Q1 2020, an estimated $53K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Haemonetics in Q3 2019 and held it in 2 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Haemonetics position peaked at $58K in Q3 2019.
  • 269 funds tracked by Wall St. Rank held Haemonetics as of Q1 2020.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2020, filed 15 Apr 2020.